

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/DE 03/04114

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/11 C12N9/12 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/88198 A (MONIA BRETT P ; FREIER SUSAN M (US); GAARDE WILLIAM A (US); ISIS PHARM) 22 November 2001 (2001-11-22)	3
Y	the whole document	1, 2, 4-27
X	WO 99/50279 A (LINGNER JOACHIM ; ANDREWS WILLIAM H (US); CECH THOMAS R (US); MORIN GR) 7 October 1999 (1999-10-07)	3
Y	the whole document	1, 2, 4-27
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *S* document member of the same patent family

Date of the actual completion of the international search

15 July 2004

Date of mailing of the international search report

02/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel (+31-70) 340-2040, Tx 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Weigl, M

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International Application No

03/04114

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHINDLER ASCAN ET AL: "Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro" INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 19, no. 1, July 2001 (2001-07), pages 25-30, XP009033724 ISSN: 1019-6439	3
Y	the whole document	1,2,4-27
X	ZHANG Y ET AL: "Effect of antisense hTERT mRNA oligodeoxynucleotide on telomerase activity of leukemic cells" CELL BIOLOGY INTERNATIONAL, vol. 26, no. 5, May 2002 (2002-05), pages 427-431, XP002288421 ISSN: 1065-6995	3
Y	the whole document	1,2,4-27
X	KOGA S ET AL: "Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA" GENE THERAPY, vol. 8, no. 8, April 2001 (2001-04), pages 654-658, XP002288422 ISSN: 0969-7128	3
Y	the whole document	1,2,4-27
X	SARETZKI GABRIELE ET AL: "Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells" CANCER GENE THERAPY, vol. 8, no. 10, October 2001 (2001-10), pages 827-834, XP002288423 ISSN: 0929-1903	3
Y	the whole document	1,2,4-27
X	YOKOYAMA YASUHIRO ET AL: "The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 273, no. 1, 24 June 2000 (2000-06-24), pages 316-321, XP002288424 ISSN: 0006-291X	3
Y	figure 1	1,2,4-27
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No.

PC 77 DE 03/04114

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	SCHERR MICHAELA ET AL: "RNA accessibility prediction: A theoretical approach is consistent with experimental studies in cell extracts" NUCLEIC ACIDS RESEARCH, vol. 28, no. 13, 1 July 2000 (2000-07-01), pages 2455-2461, XP002288425 ISSN: 0305-1048 the whole document	1-27
Y	PATZEL V ET AL: "A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 22, 15 November 1999 (1999-11-15), pages 4328-4334, XP002134406 ISSN: 0305-1048 the whole document	1-27
A	WHITE LAURA K ET AL: "Telomerase inhibitors" TRENDS IN BIOTECHNOLOGY, vol. 19, no. 3, March 2001 (2001-03), pages 114-120, XP002288426 ISSN: 0167-7799 the whole document	1-27
P,X	KRAEMER KAI ET AL: "Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells." CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 SEP 2003, vol. 9, no. 10 Pt 1, 1 September 2003 (2003-09-01), pages 3794-3800, XP002288427 ISSN: 1078-0432 cited in the application the whole document	1-27

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DE 03/04114**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 13-27 relate to a method for treatment of the human or animal body, the search was carried out and was based on the stated effects of the compound or composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/DE 03/04114

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0188198	A	22-11-2001	US 6331399 B1	18-12-2001
			US 2002045588 A1	18-04-2002
			AU 6317101 A	26-11-2001
			WO 0188198 A1	22-11-2001
WO 9950279	A	07-10-1999	US 6444650 B1	03-09-2002
			AU 3461299 A	18-10-1999
			WO 9950279 A1	07-10-1999
			US 2002173476 A1	21-11-2002

BEST AVAILABLE COPY